| Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company using its capabilities in epigenetics to discover and develop therapeutics that address medical needs in patients with cancers associated with abnormal gene expression or drug resistance. Co.'s integrated epigenetics platform enables it to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Co.'s product candidates are: CPI-0610, CPI-1205, and CPI-0209. CPI-0610 inhibits bromodomain and extra terminal domain proteins. CPI-1205 and CPI-0209 inhibit the enhancer of zeste homolog 2 protein. We show 13 historical shares outstanding datapoints in our coverage of CNST's shares outstanding history.
Understanding the changing numbers of CNST shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like CNST versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching CNST by allowing them to research CNST shares outstanding history
as well as any other stock in our coverage universe.